Government Bans High-Dose Nimesulide Painkiller Citing Health Risks

Ban on Nimesulide: Overview

The Indian government has officially banned the manufacture, sale, and distribution of all oral formulations of nimesulide that exceed 100 mg in immediate-release form. This action, aimed at protecting human health, was announced in a notification on December 29 and published in The Gazette of India.

Health Risks Associated with Nimesulide

The health ministry has expressed concerns that the continued use of higher-dose nimesulide may pose significant risks to human beings. The decision to prohibit these formulations is framed within the public interest, as safer alternatives are now available.

Understanding Nimesulide

Nimesulide is classified as a non-steroidal anti-inflammatory drug (NSAID), primarily used for pain, inflammation, and fever relief. It’s important to note that this ban specifically targets immediate-release oral formulations exceeding 100 mg.

Regulatory Background

This order is implemented under Section 26A of the Drugs and Cosmetics Act of 1940, following consultations with the Drugs Technical Advisory Board (DTAB). Consequently, manufacturers, distributors, and sellers are prohibited from producing or supplying the banned high-dose formulations.

Historical Context

Nimesulide has faced regulatory scrutiny for over a decade. In 2011, the government prohibited six drugs, including nimesulide, based on DTAB recommendations. This earlier ban also restricted its use in children under the age of 12 due to concerns about liver toxicity.

Recommendations from Health Authorities

Earlier this year, the Indian Council of Medical Research (ICMR) raised safety concerns, recommending that nimesulide use be restricted for patients under 18 and over 60 years old. Additionally, they advised that higher-dose formulations should be banned completely. Popular brands in India include Nimulid, Nimtex, Nicip, and Nise, with Nise being one of the top-selling brands.

Expert Opinion on Nimesulide Ban

Dr. Rommel Tickoo, director of internal medicine at Max Hospital, Saket, welcomed the government’s decision. He stated that this timely restriction on high-dose immediate-release nimesulide effectively addresses long-standing safety concerns, particularly concerning misuse or unsupervised use. Dr. Tickoo emphasized that with safer NSAID alternatives available, minimizing exposure to higher doses is vital for patient safety.

This structured approach breaks down the information into digestible sections optimized for search engines while maintaining clarity for readers.